Maplight Therapeutics insider plans 22,082-share sale

Maplight Therapeutics, Inc. has a filing by James Lillie indicating a proposed sale of up to 22,082 shares of common stock through Jefferies LLC, with an aggregate market value of $287,507.64.

Rhea-AI Filing Summary

Maplight Therapeutics, Inc. has a filing by James Lillie indicating a proposed sale of up to 22,082 shares of common stock through Jefferies LLC, with an aggregate market value of $287,507.64. The shares relate to vested RSUs dated July 18, 2025, and are listed for NASDAQ trading on or after August 3, 2026.

The filing also lists prior sales of Maplight common stock by James Lillie over the past three months, including transactions such as 24,811 shares sold for $713,661.87 on May 6, 2026, and several smaller trades with specified share counts and dollar amounts.

Key Figures

Shares proposed for sale: 22,082 shares Aggregate market value of proposed sale: $287,507.64 Shares outstanding: 42,000,000 shares +4 more

7 metrics

Shares proposed for sale 22,082 shares Common stock to be sold through Jefferies LLC

Aggregate market value of proposed sale $287,507.64 Value associated with 22,082 shares of common stock

Shares outstanding 42,000,000 shares Common stock referenced as outstanding for Maplight Therapeutics

Sale on May 6, 2026 24,811 shares; $713,661.87 Past 3-month sale by James Lillie

Sale on May 4, 2026 15,801 shares; $441,755.51 Past 3-month sale by James Lillie

Sale on July 16, 2026 8,547 shares; $314,386.01 Past 3-month sale by James Lillie

Sale on July 15, 2026 7,643 shares; $280,391.86 Past 3-month sale by James Lillie

Key Terms

Vested RSU, Securities To Be Sold, Securities Sold During The Past 3 Months

3 terms

Vested RSU financial

"Common | 07/18/2025 | Vested RSU | Maplight Therapeutics, Inc."

Securities To Be Sold financial

"144: Securities To Be Sold"

Securities Sold During The Past 3 Months financial

"144: Securities Sold During The Past 3 Months"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Maplight Therapeutics (MPLT) disclose in this Form 144 filing?

The filing shows James Lillie plans to sell up to 22,082 shares of Maplight Therapeutics common stock through Jefferies LLC, tied to vested RSUs from July 18, 2025, with an indicated aggregate market value of $287,507.64.

How many Maplight Therapeutics (MPLT) shares are proposed to be sold?

The filing lists a proposed sale of up to 22,082 common shares. These shares are associated with vested RSUs from July 18, 2025, and are expected to be sold on or after August 3, 2026, through Jefferies LLC on NASDAQ.

What is the reported market value of the planned MPLT share sale?

The planned sale of 22,082 shares of Maplight Therapeutics common stock has an indicated aggregate market value of $287,507.64. This value is reported alongside NASDAQ as the trading market and a planned sale date of August 3, 2026.

What past MPLT share sales by James Lillie are disclosed?

The filing lists several past sales, including 24,811 shares for $713,661.87 on May 6, 2026, 15,801 shares for $441,755.51 on May 4, 2026, and multiple additional trades in May and July 2026 with specific share counts and dollar amounts.

What is the relationship of the 22,082 MPLT shares to RSUs?

The 22,082 shares proposed for sale are identified as common stock derived from a vested RSU event dated July 18, 2025. The filing ties the securities to this vesting and lists them for potential sale beginning August 3, 2026.

How many Maplight Therapeutics (MPLT) shares are shown as outstanding?

The filing references 42,000,000 shares of Maplight Therapeutics common stock as outstanding. This figure provides context for the proposed 22,082-share sale, indicating the broader capitalization but not changing the specific amount listed for sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:01 PM Accepted by SEC EDGAR 08/03/2026 - 04:00 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001728746
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	MapLight Therapeutics, Inc.
SEC File Number	001-42914
Address of Issuer	800 CHESAPEAKE DRIVE REDWOOD CITY CALIFORNIA 94063
Phone	650-839-4360
Name of Person for Whose Account the Securities are To Be Sold	Lillie James Woodruff
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	22082	287507.64	42000000	08/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/18/2025	Vested RSU	Maplight Therapeutics, Inc.			22082	07/18/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Lillie 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	07/17/2026	2077	78716.02
James Lillie 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	07/16/2026	8547	314386.01
James Lillie 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	07/15/2026	7643	280391.86
James Lillie 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	05/07/2026	721	20387.35
James Lillie 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	05/06/2026	24811	713661.87
James Lillie 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	05/05/2026	11095	312847.49
James Lillie 800 Chesapeake Drive Redwood City CA 94063	Maplight Therapeutics, Inc.	05/04/2026	15801	441755.51

144: Remarks and Signature

Remarks	All Sales are to be made pursuant to a previously signed/adopted 10b5-1 Selling plan dated 12/29/2025, and all representations regarding material non-public information were made as of the adoption of the plan.
Date of Notice	08/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/29/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	James Lillie
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)